PHM Proposes Separation Into Two New Industry-Leading Public Companies

LAFAYETTE, LOUISIANA--(Marketwired - Sept. 20, 2016) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.

Patient Home Monitoring Corp. ("PHM") (TSX VENTURE:PHM) today announced that its Board of Directors has approved plans to separate into two companies traded on the TSX Venture Exchange (the "Exchange"):

• Viemed ("Viemed"), which will comprise PHM's market-leading provider of equipment and home therapy to service a wide array of respiratory diseases including patients that suffer from Chronic Obstructive Pulmonary Disorder ("COPD"), Chronic Respiratory Failure ("CRF") among other neuromuscular diseases;

And

• Apparo Home Care, Corp. ("Apparo"), which will comprise PHM's market-leading Durable Medical Equipment (DME) company that specializes in delivering and servicing home-based medical equipment, including oxygen therapy, sleep apnea treatment and mobility equipment.

Immediately following the closing of the transaction, which is expected to occur by the end of 2016, shareholders of PHM will own one common share in the capital of each of Viemed and Apparo for each one PHM share currently held. The transaction is intended not to generally give rise to incremental Canadian federal income tax liabilities for most PHM shareholders.

This strategic step is expected to provide each Viemed and Apparo with the focus, financial resources and flexibility to adapt quickly to the recent reimbursement rules and U.S. healthcare market dynamics while generating long-term value for shareholders.

Highlights of the Transaction:

Viemed:

• Viemed will be the nation's largest independent leader in home therapy of patients suffering from respiratory diseases that require a high level of service. The Company is currently operating in 21 states with its primary services being comprised of ventilators, oxygen, CPAPs and home sleep testing. These 21 states represent a high density of COPD patients in the U.S.
• Casey Hoyt will be Chief Executive Officer of Viemed; the Board of Directors will be announced in advance of the shareholder vote.
• On a revenue basis, Viemed will retain business units representing 30% of current revenue and is expected to generate positive adjusted EBITDA upon the split.

Apparo Highlights: